Biotechnology

Nucleus Network's 10 Step Guide to conducting Clinical Trials during a time of uncertainty

MELBOURNE, Australia, April 14, 2020 /PRNewswire/ -- A new white paper, Undertaking Phase I Clinical Trials inAustralia During a Time of Uncertainty , has been published by Nucleus Network (Nucleus),Australia's largest Phase 1 clinical trials provider....

2020-04-14 21:17 1054

WuXi Biologics (Suzhou) Successfully Passed First EMA GMP Inspection

SUZHOU, China, April 13, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platform, announced that WuXi Biologics (Suzhou) Co., Ltd. has successfully passed its first GMP inspection by the European Medicines Agency (EMA), wi...

2020-04-14 08:00 7064

Gracell to Present the First-in-human, Universal TruUCAR™ GC027 Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR Annual Meeting

SUZHOU, China and SHANGHAI, April 13, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell and gene therapy company, is pleased to announce that their first-in-human phase I data of UniversalTruUCAR™ GC027 in relapsed or refractory (R/R) T-cell acute l...

2020-04-13 21:00 1288

Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment

SONGDO, South Korea and SAN FRANCISCO, April 9, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services for Vir's SARS-CoV-2 monoclonal anti...

2020-04-10 11:39 2673

Bridge Biotherapeutics Discloses Interim Results from the First Cohort of Phase 2a Study of BBT-401, an Experimental Drug for Ulcerative Colitis

* The Interim data showed that 3 out of 9 evaluable patients on BBT-401 responded with more than 30% reduction in Total Mayo Score or 25% reduction in Partial Mayo Score * Safety and tolerability profiles remain consistent with results from Phase I trial in healthy volunteers SEONGNAM, South ...

2020-04-09 15:14 1403

Samsung Biologics named Champion in 2020 CMO Leadership Awards

SONGDO, South Korea, April 8, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) announced that it has been awarded the 2020 CMO Leadership Awards for its excellence in the Capabilities, Compatibility, Quality, Reliability, and Service categories across Big Pharma and Overall (combined Big and Sm...

2020-04-08 20:00 1283

THE.WAVE.TALK raises US$2M

SEOUL, South Korea, April 7, 2020 /PRNewswire/ -- THE.WAVE.TALK, a member company of theBorn2Global Centre, successfully attracted a funding of USD 2 million in early February from Yellowdog and Silicon Valley-based Big Basin Capital, bringing its accumulated total to approximately USD 6 million ...

2020-04-07 20:30 1332

Samsung Biologics enters into a development and manufacturing partnership with PharmAbcine for oncology and neovascular treatment

SONGDO, South Korea, April 5, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) entered into a strategic partnership with PharmAbcine for the development and manufacturing of PMC-402 pipeline, a next generation therapeutic antibody candidate to treat oncology and neovascular disorders. Under th...

2020-04-06 08:00 1131

Gracell Announces China NMPA Acceptance of Investigational New Drug Application for GC007g Cell Therapy for CD19 Positive Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

SHANGHAI and SUZHOU, China, April 3, 2020 /PRNewswire/ -- Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell & gene therapy company, is pleased to announce that China National Medical Products Administration (NMPA) has accepted Gracell's Investigational New Drug (IND) ...

2020-04-03 22:00 1885

ImmuneMed's 'hzVSF,' Used for Treatment of COVID-19 Pneumonia Patients

CHUNCHEON, South Korea, March 30, 2020 /PRNewswire/ -- 'hzVSF v13 (humanized Virus Suppressing Factor; VSF)', a treatment that can be used for a wide range of viral diseases developed by ImmuneMed, was administered onMarch 28th at Yonsei University Hospital to treat COVID-19 pneumonia patients...

2020-03-30 21:00 1064

Samsung Biologics expands leadership for CDO business

SONGDO, South Korea, March 30, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has appointedEun Young Yang as vice president of business development for the company's expanded CDO (contract development organization) business.

2020-03-30 21:00 1502

WuXi Biologics Achieved Remarkable Results in 2019

57.2% Revenue Growth to RMB3,983.7 Million 63.0% Gross Profit Growth to RMB1,658.8 Million Adjusted Net Profit Up 60.3% to RMB1,205.0 Million Diluted EPS of RMB0.76 and Adjusted Diluted EPS of RMB0.91, Increasing 58.3% and 59.6% Backlog Increased 40.2% to US$5.1 Billion Milestone Payments Surg...

2020-03-26 21:32 5911

WuXi AppTec Reports Strong 2019 Annual Results

Revenue Growth Accelerated 33.9% Year-Over-Year to RMB12,872 Million Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 38.2% Year-Over-Year toRMB2,407 Million Adjusted Diluted Non-IFRS EPS Up by 19.7% to RMB1.46[1] SHANGHAI, March 24, 2020 /PRNewswire/ -- WuXi AppTec Co., Ltd. ...

2020-03-24 18:56 6833

Novogene unveils intelligent Next Generation Sequencing delivery platform - Falcon

BEIJING, March 24, 2020 /PRNewswire/ -- Novogene recently announced Falcon, the first intelligent delivery platform for high-throughput Next Generation Sequencing (NGS). This platform represents a breakthrough in traditional NGS and will shape NGS industry standards and drive the future developme...

2020-03-24 17:07 1235

Samsung Biologics Adds Greater Expertise and Diversity to Its Board

SONGDO, South Korea, March 20, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) announced the appointment and expansion of its board of directors at its 9th annual general meeting of shareholders that took place on March 20th . In the course of expanding its business model from a contract manufa...

2020-03-20 20:00 2454

Glucagon Receptor Structures Reveal G protein Specificity Mechanism

SHANGHAI, March 19, 2020 /PRNewswire/ -- Recently, scientists at Shanghai Institute ofMateria Medica (SIMM) of Chinese Academy of Sciences, together with scientists at Institute of Biophysics (IBP) of Chinese Academy of Sciences and Monash University, determined two cryo-electron microscopy (cryo...

2020-03-20 02:00 2017

West China Hospital in Chengdu Donates COVID-19 Test Kits to Georgia

CHENGDU, China, March 16, 2020 /PRNewswire/ -- On March 12, the West China Hospital affiliated toSichuan University donated a batch of isothermal nucleic acid amplification microfluidic chip analyzers and nucleic acid test kits, which can detect and distinguish six respiratory viruses, including ...

2020-03-17 11:12 1373

EnGeneIC Announces Publication in Cancer Cell of a Scientific Paper Highlighting the Ability of EDV™ Nanocells to Mount Dual Assault on Cancer Cells

EDV™ Technology Stimulates Both Innate and Adaptive Immune Response and Confers Long-Term Survival Research Paves Way for Treatment of Drug-Resistant, End-Stage Cancers NEW YORK and SYDNEY, March 17, 2020 /PRNewswire/ -- EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its ...

2020-03-17 00:35 2039

Huami Corporation Reports Fourth Quarter and Full Year 2019 Unaudited Financial Results

BEIJING, March 13, 2020 /PRNewswire/ -- Huami Corporation ("Huami" or the "Company") (NYSE: HMI), a cloud-based healthcare services provider with world-leading smart wearable technology, today announced its unaudited financial results for the fourth quarter and full year endedDecember 31, 2019. ...

2020-03-13 18:00 10347

China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2019

BEIJING, March 12, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its financial results for the fourth quarter and fiscal year of 2019. Fourt...

2020-03-13 05:00 10299

Week's Top Stories